BRTX vs. BDSX, CCM, BMGL, BNR, MRAI, ENZ, MGRX, OTRK, SSY, and BGLC
Should you be buying BioRestorative Therapies stock or one of its competitors? The main competitors of BioRestorative Therapies include Biodesix (BDSX), Concord Medical Services (CCM), Basel Medical Group (BMGL), Burning Rock Biotech (BNR), Marpai (MRAI), Enzo Biochem (ENZ), Mangoceuticals (MGRX), Ontrak (OTRK), SunLink Health Systems (SSY), and BioNexus Gene Lab (BGLC). These companies are all part of the "healthcare" industry.
BioRestorative Therapies vs.
Biodesix (NASDAQ:BDSX) and BioRestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, Biodesix had 5 more articles in the media than BioRestorative Therapies. MarketBeat recorded 9 mentions for Biodesix and 4 mentions for BioRestorative Therapies. Biodesix's average media sentiment score of -0.48 beat BioRestorative Therapies' score of -0.60 indicating that Biodesix is being referred to more favorably in the media.
Biodesix has a net margin of -66.84% compared to BioRestorative Therapies' net margin of -2,697.08%. BioRestorative Therapies' return on equity of -98.49% beat Biodesix's return on equity.
Biodesix currently has a consensus price target of $1.75, indicating a potential upside of 391.71%. BioRestorative Therapies has a consensus price target of $18.00, indicating a potential upside of 1,028.53%. Given BioRestorative Therapies' stronger consensus rating and higher probable upside, analysts plainly believe BioRestorative Therapies is more favorable than Biodesix.
BioRestorative Therapies has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than BioRestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Biodesix has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 77.73, meaning that its share price is 7,673% more volatile than the S&P 500.
Biodesix received 33 more outperform votes than BioRestorative Therapies when rated by MarketBeat users. However, 100.00% of users gave BioRestorative Therapies an outperform vote while only 76.09% of users gave Biodesix an outperform vote.
21.0% of Biodesix shares are owned by institutional investors. Comparatively, 69.4% of BioRestorative Therapies shares are owned by institutional investors. 69.2% of Biodesix shares are owned by company insiders. Comparatively, 25.5% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Biodesix beats BioRestorative Therapies on 10 of the 18 factors compared between the two stocks.
Get BioRestorative Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioRestorative Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:BRTX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy BRTX Stock Free BRTX Stock Alerts